相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud et al.
NATURE REVIEWS ENDOCRINOLOGY (2023)
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut et al.
ENDOCRINE REVIEWS (2023)
Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Rohit Loomba et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)
Weight loss did not modify macronutrient specific response of hormones and satiety in overweight and obese people without metabolic disease- results from a clinical trial
Linna Li et al.
CLINICAL NUTRITION (2022)
Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases
Jiasheng Wang et al.
ENDOCRINE RESEARCH (2022)
A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study)
Jayasree Loganathan et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2022)
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar et al.
NATURE MEDICINE (2022)
Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
W. David Strain et al.
STROKE (2022)
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
MOLECULAR METABOLISM (2022)
Glucose- and Bile Acid-Stimulated Secretion of Gut Hormones in the Isolated Perfused Intestine Is Not Impaired in Diet-Induced Obese Mice
Jenna E. Hunt et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp et al.
PHARMACOLOGICAL RESEARCH (2022)
Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
Monica Imbernon et al.
CELL METABOLISM (2022)
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
Adem Y Dawed et al.
Lancet Diabetes & Endocrinology (2022)
Glucagon-like Peptide-1 receptor Tie2+cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
Brent A. McLean et al.
MOLECULAR METABOLISM (2022)
Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
Weiting Hu et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Activation
Katherine N. Cahil et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2022)
Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation
Chi Kin Wong et al.
CELL METABOLISM (2022)
GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes
Sebastian Moller Nguyen Heimburger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review
Niklas Reich et al.
FRONTIERS IN NEUROSCIENCE (2022)
Genetic disruption of the Gipr in Apoe-/- mice promotes atherosclerosis
Gemma Pujadas et al.
MOLECULAR METABOLISM (2022)
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
Brent A. McLean et al.
ENDOCRINE REVIEWS (2021)
Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
Justyna Modrzynska et al.
ENDOCRINE CONNECTIONS (2021)
Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms
Ida Marie Modvig et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2021)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes
Kirsten Dahl et al.
DIABETES OBESITY & METABOLISM (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
K. El et al.
SCIENCE ADVANCES (2021)
Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study
Fanny Chasseloup et al.
Lancet Diabetes & Endocrinology (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Reagents and models for detecting endogenous GLP1R and GIPR
Julia Ast et al.
EBIOMEDICINE (2021)
Differential importance of endothelia and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
Brent A. McLean et al.
JCI INSIGHT (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism
Diba Borgmann et al.
CELL METABOLISM (2021)
Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
Rasmus S. Ripa et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2021)
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models
Tito Borner et al.
DIABETES (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
David Z. I. Cherney et al.
MED (2021)
The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanism
Christina N. Heiss et al.
CELL REPORTS (2021)
Central and peripheral GLP-1 systems independently suppress eating
Daniel I. Brierley et al.
NATURE METABOLISM (2021)
Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction
Florian Kahles et al.
EUROPEAN HEART JOURNAL (2020)
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Laerke S. Gasbjerg et al.
PEPTIDES (2020)
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
Natasha C. Bergmann et al.
DIABETES CARE (2020)
GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study
Helga Ellingsgaard et al.
DIABETOLOGIA (2020)
Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α
M. Ahsan Siraj et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass
Caroline C. Ohrstrom et al.
OBESITY SURGERY (2020)
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Hertzel C. Gerstein et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry
Paula M. Hale et al.
THYROID (2020)
The gut hormone receptor GIPR links energy availability to the control of hematopoiesis
Gemma Pujadas et al.
MOLECULAR METABOLISM (2020)
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selectivelong-acting GLP-1 receptor agonists
Shweta Urva et al.
DIABETES OBESITY & METABOLISM (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Tali Cukierman-Yaffe et al.
LANCET NEUROLOGY (2020)
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio et al.
MOLECULAR METABOLISM (2020)
Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes
Okechi S. Oduori et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women
Julia Otten et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Youngmi Song et al.
CELL METABOLISM (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Laerke S. Gasbjerg et al.
DIABETES (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
Glucagon lowers glycemia when β cells are active
Megan E. Capozzi et al.
JCI INSIGHT (2019)
GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Fernanda Dana Mantelmacher et al.
NATURE METABOLISM (2019)
Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction
John R. Ussher et al.
CELL METABOLISM (2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Elizabeth A. Killion et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Insulin Secretion Depends on Intra- islet Glucagon Signaling
Berit Svendsen et al.
CELL REPORTS (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
GLP-1 Receptor Expression Within the Human Heart
Laurie L. Baggio et al.
ENDOCRINOLOGY (2018)
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
Anders Jorsal et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis
Fernanda Dana Mantelmacher et al.
JOURNAL OF IMMUNOLOGY (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lorene J. Lebrun et al.
CELL REPORTS (2017)
The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
Laurie L. Baggio et al.
MOLECULAR METABOLISM (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease
Corinna Lebherz et al.
AMERICAN JOURNAL OF MEDICINE (2017)
GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release
A. H. Sparre-Ulrich et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium
Fiona M. Gribble et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 78 (2016)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
Asa Segerstolpe et al.
CELL METABOLISM (2016)
Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models
Munenori Hiromura et al.
CIRCULATION JOURNAL (2016)
Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Eva W. Iepsen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery
M. S. Svane et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial
Kenneth B. Margulies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Line S. Bisgaard et al.
PLOS ONE (2016)
Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice
Shu Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
Bernardo Yusta et al.
DIABETES (2015)
GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study
Kristine Faerch et al.
DIABETES (2015)
GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial
Oezlem Goegebakan et al.
DIABETOLOGIA (2015)
Incretin Effect After Oral Amino Acid Ingestion in Humans
Ola Lindgren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
Beatrice Waser et al.
MODERN PATHOLOGY (2015)
Lipopolysaccharides-Mediated Increase in Glucose-Stimulated Insulin Secretion: Involvement of the GLP-1 Pathway
Anh Thoai Nguyen et al.
DIABETES (2014)
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect
Stephanie Sisley et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation
Chen Varol et al.
JOURNAL OF IMMUNOLOGY (2014)
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
Astrid Plamboeck et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
Mohammad Hossein Noyan-Ashraf et al.
CIRCULATION (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
Minsuk Kim et al.
NATURE MEDICINE (2013)
Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?
Christina Daousi et al.
REGULATORY PEPTIDES (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose-Absorption and Glucose-Dependent Incretin Secretion
Valentin Gorboulev et al.
DIABETES (2012)
Glucose-Dependent Insulinotropic Polypeptide Receptors in Most Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Beatrice Waser et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Exenatide Exerts a Potent Antiinflammatory Effect
Ajay Chaudhuri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn's disease
Meike Koerner et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
A Novel Human-Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1
James T. Patterson et al.
ACS CHEMICAL BIOLOGY (2011)
GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
Nikolaos Mentis et al.
DIABETES (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
Jonatan I. Bagger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard et al.
NATURE MEDICINE (2011)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
I. Hadjiyanni et al.
DIABETOLOGIA (2010)
Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients
U. Pugazhenthi et al.
DIABETOLOGIA (2010)
Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
Kiwon Ban et al.
ENDOCRINOLOGY (2010)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
P. V. Hojberg et al.
DIABETOLOGIA (2009)
Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion
Sara Edfalk et al.
DIABETES (2008)
A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release
Zhi-Liang Chu et al.
ENDOCRINOLOGY (2008)
Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet
Matthew C. Althage et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The Immunological Genome Project: networks of gene expression in immune cells
Tracy S. P. Heng et al.
NATURE IMMUNOLOGY (2008)
GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
Meike Koerner et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1
CF Nagell et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2004)
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
MJ During et al.
NATURE MEDICINE (2003)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K Miyawaki et al.
NATURE MEDICINE (2002)
分享论文
